Medexus Pharmaceuticals Inc.

OTCPK:MEDX.F Stock Report

Market Cap: US$57.7m

Medexus Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:MEDX.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Feb 25BuyUS$34,954Brendon BuschmanIndividual15,000US$2.42
06 Dec 24BuyUS$10,970Michael MuellerIndividual7,000US$2.04
06 Dec 24SellUS$7,080Michael MuellerIndividual3,500US$2.02
19 Sep 24BuyUS$5,528Kenneth d'EntremontIndividual3,000US$1.84
26 Aug 24BuyUS$9,054Brendon BuschmanIndividual5,000US$1.81
28 Jun 24BuyUS$7,854Kenneth d'EntremontIndividual6,000US$1.32
28 Jun 24BuyUS$19,152Brendon BuschmanIndividual15,000US$1.28

Insider Trading Volume

Insider Buying: MEDX.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MEDX.F?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,009,7913.13%
Individual Insiders2,392,6167.42%
General Public28,855,59689.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 31.9%.

Top Shareholders

Top 14 shareholders own 10.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.61%
Kenneth d'Entremont
1,486,807US$2.7m0.61%no data
2.52%
Armistice Capital LLC
812,000US$1.5m0%0.04%
1.72%
Stephen Nelson
554,280US$991.8k0%no data
0.4%
Perritt Capital Management, Inc.
130,100US$232.8k-3.7%0.12%
0.3%
Michael Mueller
97,070US$173.7k0%no data
0.26%
Brendon Buschman
83,311US$149.1k22%no data
0.2%
GoodWood Inc.
66,024US$118.1k0%4.67%
0.2%
Benoit Gravel
63,532US$113.7k0%no data
0.084%
Richard Labelle
27,005US$48.3k17.7%no data
0.076%
Harmony Garges
24,412US$43.7k0%no data
0.076%
Menassie Taddese
24,412US$43.7k0%no data
0.064%
Ian Wildgoose Brown
20,634US$36.9k0%no data
0.035%
Nancy Phelan
11,153US$20.0k0%no data
0.0052%
The Michael and Carol Mueller Family Foundation, Endowment Arm
1,667US$3.0k0%100.0%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 00:19
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medexus Pharmaceuticals Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity